Volume 9, Issue 2 (2018)
JMBS 2018, 9(2): 247-258 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shankaii Z, Firoozabadi S. Electroporation of Cells Using Electric and Magnetic Fields with Approach of Cancer Treatment: A Review Article. JMBS 2018; 9 (2) :247-258
URL: http://biot.modares.ac.ir/article-22-24719-en.html
URL: http://biot.modares.ac.ir/article-22-24719-en.html
1- Medical Physics Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran
2- Medical Physics Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran, Medical Physics Department, Medical Sciences Faculty, Tarbiat Modares University, Nasr Bridge, Jalal-Ale-Ahmad Highway, Tehran, Iran , pourmir@modares.ac.ir
2- Medical Physics Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran, Medical Physics Department, Medical Sciences Faculty, Tarbiat Modares University, Nasr Bridge, Jalal-Ale-Ahmad Highway, Tehran, Iran , pourmir@modares.ac.ir
Abstract: (4076 Views)
Introduction: Sometimes materials that do not have the ability to penetrate into the membrane will need to be widely entered into the cell. Therapeutic methods are among the methods that sometimes feel this change in permeability when using different drugs and genes. Electroporation (EP) is a new technique that increases the permeability of cell membranes when cells exposed to an external electric field more than a threshold voltage and is used to introduce different non-permanent molecules. The major application of EP in the treatment of cancer combined with chemotherapy drugs such as Bleomycin and Cisplatin is electrochemotherapy. The aim of this study was to review the electroporation of cells, using electric and magnetic fields with approach of cancer treatment.
Conclusion: In pre-clinical studies, this method has first been optimized on the animal and cell, and after clinical trials, today, the standard and clinical protocol of electrochemotherapy has been proposed as a safe and effective method for some tumors. This is a simple method with minimal side effects, but in new pre-clinical studies, with the use of high frequency electrons, low electromagnetic fields, and the use of pulsed magnetic fields, it has been tried to overcome the limitations of this standard method.
Conclusion: In pre-clinical studies, this method has first been optimized on the animal and cell, and after clinical trials, today, the standard and clinical protocol of electrochemotherapy has been proposed as a safe and effective method for some tumors. This is a simple method with minimal side effects, but in new pre-clinical studies, with the use of high frequency electrons, low electromagnetic fields, and the use of pulsed magnetic fields, it has been tried to overcome the limitations of this standard method.
Subject:
Agricultural Biotechnology
Received: 2018/09/3 | Accepted: 2018/09/3 | Published: 2018/10/2
Received: 2018/09/3 | Accepted: 2018/09/3 | Published: 2018/10/2
References
1. Weaver JC. Electroporation theory, concepts and mechanisms. Methods Mol Biol. 1995;47:1-26. [Link]
2. Davalos R, Huang Y, Rubinsky B. Electroporation: BIO-electrochemical mass transfer at the nano scale. Microscale Thermophys Eng. 2000;4(3):147-59. [Link] [DOI:10.1080/10893950050148115]
3. Neumann E, Kakorin S, Toensing K. Principles of membrane electroporation and transport of macromolecules. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 1-35. [Link] [DOI:10.1385/1-59259-080-2:1]
4. Pliquett U, Gift EA, Weaver JC. Determination of the electric field and anomalous heating caused by exponential pulses with aluminum electrodes in electroporation experiments. Bioelectrochem Bioenerg. 1996;39(1):39-53. [Link] [DOI:10.1016/0302-4598(95)05031-0]
5. Lee EW, Gehl J, Kee ST. Introduction to electroporation. In: Kee ST, Gehl J, Lee EW, editors. Clinical aspects of electroporation. Heidelberg: Springer Science & Business Media; 2011. pp. 3-8. [Link] [DOI:10.1007/978-1-4419-8363-3_1]
6. Gehl J. Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand. 2003;177(4):437-47. [Link] [DOI:10.1046/j.1365-201X.2003.01093.x]
7. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat. 2005;4(6):699-705. [Link] [DOI:10.1177/153303460500400615]
8. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295-300. [Link] [DOI:10.1177/153303460700600405]
9. Rubinsky J, Onik G, Mikus P, Rubinsky B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J Urol. 2008;180(6):2668-74. [Link] [DOI:10.1016/j.juro.2008.08.003]
10. Nickfarjam A, Firoozabadi SMP, Kalaghchi B. A Multi Objective Genetic Algorithm (MOGA) for optimizing thermal and electrical distribution in tumor ablation by irreversible electroporation. J Biomed Phys Eng. 2013;3(1):13-24. [Link]
11. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol. 2008;34(2):232-40. [Link] [DOI:10.1016/j.ejso.2007.05.016]
12. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl. 2006;4(11):14-25. [Link] [DOI:10.1016/j.ejcsup.2006.08.003]
13. Heller R, Gilbert R, Jaroszeski MJ. Clinical trial for solid tumors using electrochemotherapy. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 137-56. [Link] [DOI:10.1385/1-59259-080-2:137]
14. Pavlin M, Kandušer M, Reberšek M, Pucihar G, Hart FX, Magjarević R, et al. Effect of cell electroporation on the conductivity of a cell suspension. Biophys J. 2005;88(6):4378-90. [Link] [DOI:10.1529/biophysj.104.048975]
15. Teissié J, Escoffre J, Rols M, Golzio M. Time dependence of electric field effects on cell membranes, a review for a critical selection of pulse duration for therapeutical applications. Radiol Oncol. 2008;42(4):196-206. [Link] [DOI:10.2478/v10019-008-0016-2]
16. Towhidi L, Kotnik T, Pucihar G, Firoozabadi SM, Mozdarani H, Miklavcic D. Variability of the minimal transmembrane voltage resulting in detectable membrane electroporation. Electromagn Biol Med. 2008;27(4):372-85. [Link] [DOI:10.1080/15368370802394644]
17. Towhidi L, Firoozabadi SM, Mozdarani H, Kotnik T, Pucihar G, Miklavcic D. Effect of cell size and shape on electric field threshold and critical transmembrane voltage for electroporation. Iran J Med Phys. 2008;5(3-4):1-14. [Persian] [Link]
18. Stampflj R. Reversible electrical breakdown of the excitable membrane of a Ranvier node. An Acad Brasil Ciens. 1958;30(1):57-61. [Link]
19. Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol. 1972;10(1):279-90. [Link] [DOI:10.1007/BF01867861]
20. Hui SW. Effects of pulse length and strength on electroporation efficiency. Methods Mol Biol. 1995;55:29-40. [Link]
21. Heller R. Overview of electroporation. Technol Cancer Res Treat. 2002;1(5):317-8. [Link] [DOI:10.1177/153303460200100501]
22. Serša G. Electrochemotherapy. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 119-36. [Link] [DOI:10.1385/1-59259-080-2:119]
23. Mir LM. Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl. 2006;4(11):38-44. [Link] [DOI:10.1016/j.ejcsup.2006.08.005]
24. Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric pulses. Eur J Cancer. 1999;35(4):672-7. [Link] [DOI:10.1016/S0959-8049(98)00426-2]
25. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer. 2002;87(9):1047-54. [Link] [DOI:10.1038/sj.bjc.6600606]
26. Jarm T, Wickramasinghe YA, Deakin M, Cemazar M, Elder J, Rolfe P, et al. Blood perfusion of subcutaneous tumours in mice following the application of low-level direct electric current. Adv Exp Med Biol. 1999;471:497-506. [Link] [DOI:10.1007/978-1-4615-4717-4_59]
27. Mir LM, Orlowski S. The basis of electrochemotheraphy. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 99-117. [Link] [DOI:10.1385/1-59259-080-2:99]
28. Puc M, Kotnik T, Mir LM, Miklavcic D. Quantitative model of small molecules uptake after in vitro cell electropermeabilization. Bioelectrochemistry. 2003;60(1-2):1-10. [Link] [DOI:10.1016/S1567-5394(03)00021-5]
29. Van Deurs B, Sandvig K, Petersen OW, Olsnes S, Simons K, Griffiths G. Estimation of the amount of internalized ricin that reaches the trans-Golgi network. J Cell Biol. 1988;106(2):253-67. [Link] [DOI:10.1083/jcb.106.2.253]
30. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J Jr, et al. Internalisation of the bleomycin molecules responsible for bleomycin toxicity: A receptor-mediated endocytosis mechanism. Biochem Pharmacol. 1999;57(1):45-56. [Link] [DOI:10.1016/S0006-2952(98)00282-2]
31. Silve A, Mir LM. Cell electropermeabilization and cellular uptake of small molecules: The electrochemotherapy concept. In: Kee ST, Gehl J, Lee EW, editors. Clinical aspects of electroporation. Heidelberg: Springer Science & Business Media; 2011. pp. 69-82. [Link] [DOI:10.1007/978-1-4419-8363-3_6]
32. Shil P, Bidaye S, Vidyasagar PB. Analysing the effects of surface distribution of pores in cell electroporation for a cell membrane containing cholesterol. J Phys D Appl Phys. 2008;41(5):055502. [Link] [DOI:10.1088/0022-3727/41/5/055502]
33. Hall E. Radiobiology for the radiologist. Mozdarani H, translator. Tehran: Tarbiat Modares University; 2000. [Persian] [Link]
34. Cemazar M, Golzio M, Escoffre JM, Couderc B, Sersa G, Teissié J. In vivo imaging of tumor growth after electrochemotherapy with cisplatin. Biochem Biophys Res Commun. 2006;348(3):997-1002. [Link] [DOI:10.1016/j.bbrc.2006.07.132]
35. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer. 2001;84(9):1272-9. [Link] [DOI:10.1054/bjoc.2001.1786]
36. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: Implications in treatment of bleeding metastases. Expert Rev Anticancer Ther. 2010;10(5):729-46. [Link] [DOI:10.1586/era.10.43]
37. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer. 2008;98(2):388-98. [Link] [DOI:10.1038/sj.bjc.6604168]
38. Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res. 2009;335(1):241-8. [Link] [DOI:10.1007/s00441-008-0646-0]
39. Raeisi E, Firoozabadi SM, Hajizadeh S, Rajabi H, Hassan ZM. The effect of high-frequency electric pulses on tumor blood flow in vivo. J Membr Biol. 2010;236(1):163-6. [Link] [DOI:10.1007/s00232-010-9288-8]
40. Sersa G, Kranjc S, Scancar J, Krzan M, Cemazar M. Electrochemotherapy of mouse sarcoma tumors using electric pulse trains with repetition frequencies of 1 Hz and 5 kHz. J Membr Biol. 2010;236(1):155-62. [Link] [DOI:10.1007/s00232-010-9268-z]
41. Valic B, Golzio M, Pavlin M, Schatz A, Faurie C, Gabriel B, et al. Effect of electric field induced transmembrane potential on spheroidal cells: Theory and experiment. Eur Biophys J. 2003;32(6):519-28. [Link] [DOI:10.1007/s00249-003-0296-9]
42. Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: Evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer. 2001;84(4):565-70. [Link] [DOI:10.1054/bjoc.2000.1625]
43. Sentjurc M, Cemazar M, Sersa G. EPR oximetry of tumors in vivo in cancer therapy. Spectrochim Acta A Mol Biomol Spectrosc. 2004;60(6):1379-85. [Link] [DOI:10.1016/j.saa.2003.10.036]
44. Engström PE, Persson BR, Salford LG. Studies of in vivo electropermeabilization by gamma camera measurements of (99m) Tc-DTPA. Biochim Biophys Acta. 1999;1473(2-3):321-8. [Link] [DOI:10.1016/S0304-4165(99)00199-3]
45. Snoj M, Cemazar M, Slekovec Kolar B, Sersa G. Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat Med J. 2007;48(3):391-5. [Link]
46. Davalos RV, Rubinsky B, Otten DM. A feasibility study for electrical impedance tomography as a means to monitor tissue electroporation for molecular medicine. IEEE Trans Biomed Eng. 2002;49(4):400-3. [Link] [DOI:10.1109/10.991168]
47. Davalos RV, Otten DM, Mir LM, Rubinsky B. Electrical impedance tomography for imaging tissue electroporation. IEEE Trans Biomed Eng. 2004;51(5):761-7. [Link] [DOI:10.1109/TBME.2004.824148]
48. Shankayi Z, Firoozabadi SM. Antitumor efficiency of electrochemotherapy by high and low frequencies and repetitive therapy in the treatment of invasive ductal carcinoma in Balb/c Mice. Cell J. 2012;14(2):110-5. [Link]
49. Dev SB, Hofmann GA, Nanda GS. Treatment of human pancreatic tumors xenografted in nude mice by chemotherapy combined with pulsed electric fields. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 277-83. [Link] [DOI:10.1385/1-59259-080-2:277]
50. Jaroszeski MJ, Gilbert R, Heller R. Treatment of liver malignancies with electrochemotherapy in rat model. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 319-26.
https://doi.org/10.1385/1-59259-080-2:319 [Link] [DOI:10.1385/1592590802]
51. Salford LG, Engström P, Persson BR. Treatment of rat glioma with electrochemotherapy. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 313-7. [Link] [DOI:10.1385/1-59259-080-2:313]
52. Sersa G, Kranjc S, Cemazar M. Improvement of combined modality therapy with cispelatin and radiation using electrochemotherapy of tumors. Int J Radiat Oncol Biol Phys. 2000;46(4):1037-41. [Link] [DOI:10.1016/S0360-3016(99)00464-2]
53. Spugnini EP, Citro G, Dotsinsky I, Mudrov N, Mellone P, Baldi A. Ganglioneuroblastoma in a cat: A rare neoplasm treated with electrochemotherapy. Vet J. 2008;178(2):291-3. [Link] [DOI:10.1016/j.tvjl.2007.08.014]
54. Blad B, Persson B. An electrical impedance indicator to assess electropermeabilisation in tissue, a preliminary study. ITBM-RBM. 2005;26(5-6):328-32. [French] [Link] [DOI:10.1016/j.rbmret.2005.02.004]
55. Ivorra A, Rubinsky B. In vivo electrical impedance measurements during and after electroporation of rat liver. Bioelectrochemistry. 2007;70(2):287-95. [Link] [DOI:10.1016/j.bioelechem.2006.10.005]
56. Sersa G, Cufer T, Paulin SM, Cemazar M, Snoj M. Electrochemotherapy of chest wall breast cancer recurrence. Cancer Treat Rev. 2012;38(5):379-86. [Link] [DOI:10.1016/j.ctrv.2011.07.006]
57. Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. Eur J Cancer Suppl. 2006;4(11):52-9. [Link] [DOI:10.1016/j.ejcsup.2006.08.007]
58. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O'Reily S, et al. Electrochemotherapy: Aspects of preclinical development and early clinical experience. Ann Surg. 2007;245(3):469-79. [Link] [DOI:10.1097/01.sla.0000250419.36053.33]
59. Hafmann GA. Instrumentation and electrodes for in vivo electroporation. In: Jaroszeski MJ, Heller R, Gilbert R, editors. Electrochemotherapy, electrogenetherapy, and transdermal drug delivery, methods in molecular medicine. 37th Volume. New York City: Humana Press; 2000. pp. 37-58. [Link] [DOI:10.1385/1-59259-080-2:37]
60. Rebersek M, Corović S, Sersa G, Miklavcic D. Electrode commutation sequence for honeycomb arrangement of electrodes in electrochemotherapy and corresponding electric field distribution. Bioelectrochemistry. 2008;74(1):26-31. [Link] [DOI:10.1016/j.bioelechem.2008.03.001]
61. Rabussay D. Applicator and electrode design for in vivo DNA delivery by electroporation. In: Li S, editor. Electroporation protocols, methods in molecular biology™. 423rd Volume. New York City: Humana Press; 2008. pp. 35-59. [Link]
62. Hofmann GA. Instrumentation. In: Nickoloff JA, editor. Plant cell electroporation and electrofusion protocols, methods in molecular biology™. 55th Volume. Totowa: Springer; 1995. pp. 41-59.
https://doi.org/10.1385/0-89603-304-X:41 [Link] [DOI:10.1385/0-89603-328-7:41]
63. Mansourian M, Firoozabadi SM, Shankayi Z, Hassan ZM. Magnetic fields with frequency of 217 Hz can reduce cell apoptosis caused by electrochemotherapy. Electromagn Biol Med. 2013;32(1):70- 8. [Link] [DOI:10.3109/15368378.2012.708693]
64. Shankayi Z, Firoozabadi SM, Saraf Hassan Z. Comparison of low voltage amplitude electrochemotherapy with 1 Hz and 5 kHz frequency in volume reduction of mouse mammary tumor in Balb/c Mice. Koomesh. 2012;13(4):486-90. [Persian] [Link]
65. Shankayi Z, Firoozabadi SM, Hassan ZS. Optimization of electric pulse amplitude and frequency in vitro for low voltage and high frequency electrochemotherapy. J Membr Biol. 2014;247(2):147-54. [Link] [DOI:10.1007/s00232-013-9617-9]
66. Shankayi Z, Pourmirjafari Firoozabadi SM, Saraf Hassan Z. The endothelial permeability increased by low voltage and high frequency electroporation. J Biomed Phys Eng. 2013;3(3):87-92. [Link]
67. Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. Eur J Cancer Suppl. 2006;4(11):45-51. [Link] [DOI:10.1016/j.ejcsup.2006.08.006]
68. Wilke N, Hibert C, O'Brien J, Morrissey A. Silicon microneedle electrode array with temperature monitoring for electroporation. Sens Actuator A Phys. 2005;123-124:319-25. [Link]
69. Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, et al. Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett. 2006;232(2):300-10. [Link] [DOI:10.1016/j.canlet.2005.03.057]
70. Horiuchi A, Nikaido T, Mitsushita J, Toki T, Konishi I, Fujii S. Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: A study of human uterine leiomyosarcomas in nude mice. Int J Cancer. 2000;88(4):640-4.
https://doi.org/10.1002/1097-0215(20001115)88:4<640::AID-IJC19>3.0.CO;2-K [Link] [DOI:10.1002/1097-0215(20001115)88:43.0.CO;2-K]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |